Novo Nordisk Sets Sights on Milan Data Drop and London Strategy Day as Buyback Rolls On
Published on 09/17/2026 at 13:01 | Editorial boerse-global.de
Novo Nordisk has mapped out a busy autumn calendar, with a capital markets day in London on 21 September followed by a heavy presence at the European Association for the Study of Diabetes annual meeting in Milan from 28 September to 2 October. The Danish drugmaker will use the Milan congress to unveil data from its cardiometabolic pipeline across 44 presentations, covering the oral version of Wegovy, the drug candidate CagriSema and Zenagamtid.
The timing matters. Results for the oral formulation of Wegovy and for the CagriSema combination sit at the centre of attention for clinicians and investors alike, since they could signal how the company's competitive position in metabolic therapies will shape up.
Management Push for a Sharper Culture
Behind the science, Novo Nordisk is reworking its internal organisation to counter tougher competition in obesity treatments. CEO Mike Doustdar urged staff on Tuesday to adopt a more customer-focused culture, according to Reuters, with the aim of clawing back ground lost in the market for anti-obesity medicines.
That appeal came a day after the company said it would trade under the shortened brand name "Novo" in day-to-day use, a move management tied to a broader cultural reset. The rebrand is accompanied by the tagline "Lasting Health Starts Now" and a reworked corporate culture dubbed "The Novo Way".
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Setbacks Beyond the Core Business
Pressure on the leadership has mounted as diversification away from diabetes and obesity proves harder than planned. On 7 September the group halted two Phase 3 trials, HERMES and ATHENA, testing the experimental cardiovascular drug Ziltivekimab. An independent data monitoring committee had judged that a clinically meaningful benefit in the two studies was unlikely.
That development freeze dimmed hopes of quickly building new pillars beyond the established GLP-1 franchise, raising the stakes for Novo Nordisk to defend its core business against rivals while opening fresh indications for proven compounds.
Widening the GLP-1 Footprint
Even with the cardiovascular stumble, the company has flagged progress in extending existing medicines. On 10 September Chinese regulators cleared Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — the first approval of a GLP-1 receptor agonist for the severe liver disease in that market. Two days earlier, Novo Nordisk released late-stage data on semaglutide showing that after 68 weeks of treatment, 40.4% of participating children aged 6 to under 12 were no longer classified as obese, provided they adhered fully to the therapy.
For investors, these developments make clear that near-term earnings power still rests mainly on market penetration and indication expansion of the GLP-1 product family, while management works in parallel to sharpen its internal edge.
Buyback Continues Ahead of Key Dates
Alongside preparations for London and Milan, the Danish group is pressing on with its share repurchase programme. Transactions for the acquisition of B shares have totalled DKK 9,326,186,478 since 4 February, the company said on Monday, leaving it holding 1.1% of its share capital in treasury. The buyback underscores efforts to return capital to shareholders as the company lines up new initiatives in its core business.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Market Backdrop
The convergence of strategic repositioning and pending study data is drawing close attention in financial markets. A little over a week ago, Morgan Stanley cut its rating on Novo Nordisk. The upcoming events in London and Milan give the company a chance to set fresh accents on operational development and clinical research.
In pre-market trading the stock changed hands at EUR 36.48, having closed at EUR 36.59. Since the start of the year the shares have fallen 17%, leaving them 34% below their 52-week high of EUR 54.86.
Ad
Novo Nordisk Stock: New Analysis - 17 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
